Life’s full of enough breathtaking moments without IPF

The HARBOR Study is currently enrolling individuals between 18 and 80 years of age who have been diagnosed with idiopathic pulmonary fibrosis (IPF).

Contact us for more information

Who May Qualify

Eligible participants must:

  • Be between 18 and 80 years of age
  • Have a current diagnosis of IPF (the date of initial diagnosis of IPF should be between one and seven years prior to screening)
  • Not be currently receiving treatment with specific IPF medicines due to:
    • Intolerance or not responding to approved IPF medicines
    • Ineligibility to receive approved IPF medicines
    • Declining approved IPF medicines
  • Not have had a cancerous condition in the past five years (except successfully treated basal/squamous cell carcinoma of the skin or cervical cancer)

There are additional eligibility criteria, which the study team will discuss with participants.

Study Participation

Participants will be chosen at random to receive either the potential medicine or the placebo, which looks just like the potential medicine but does not contain active ingredients. Both the potential medicine and the placebo are tablets taken orally twice daily.

Participants will be asked to attend 12 visits to the study site and have two phone calls with the study team throughout the study. The total length of participation is approximately 64 weeks and consists of:

  • Screening – This period can last up to eight weeks. The purpose of this period is to evaluate interested individuals to make sure the study is a good match for them.
  • Treatment – This period lasts 52 weeks and is double-blind, which means neither the participant nor the study doctor will know whether the participant is receiving the potential medicine or the placebo. During this period, participants will take their assigned study treatment and attend regular visits at the study site for the doctors and nurses to check on their health. Participants who complete the 52-week treatment period may be eligible to enter a 52-week open-label extension study. “Open label” means that the participant will receive the potential medicine, and everyone will be aware they are taking the potential medicine and not the placebo.
  • Safety follow-up – This visit occurs four weeks after the last dose of the potential medicine. Participants who choose not to enter the open-label extension study will have this safety follow-up visit. The purpose of this visit is to check on participants’ health after stopping the potential medicine.

Throughout the study, the study doctor may perform a number of tests and procedures, including but not limited to:

  • Recording medical history
  • Conducting a physical exam
  • Measuring vital signs
  • Performing electrocardiograms
  • Collecting blood and urine samples
Contact us for more information